SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)